Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Madrigal Pharmaceuticals stock | $119.09

Own Madrigal Pharmaceuticals stock in just a few minutes.

Fact checked

Madrigal Pharmaceuticals, Inc is a biotechnology business based in the US. Madrigal Pharmaceuticals shares (MDGL) are listed on the NASDAQ and all prices are listed in US Dollars. Madrigal Pharmaceuticals employs 29 staff and has a market cap (total outstanding shares value) of USD$1.8 billion.

How to buy shares in Madrigal Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Madrigal Pharmaceuticals. Find the stock by name or ticker symbol: MDGL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Madrigal Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$119.09, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Madrigal Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Madrigal Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Madrigal Pharmaceuticals share price

Use our graph to track the performance of MDGL stocks over time.

Madrigal Pharmaceuticals shares at a glance

Information last updated 2020-12-01.
Latest market closeUSD$119.09
52-week rangeUSD$56.82 - USD$136.81
50-day moving average USD$124.792
200-day moving average USD$114.5553
Wall St. target priceUSD$170
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.567

Buy Madrigal Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Madrigal Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Madrigal Pharmaceuticals price performance over time

Historical closes compared with the close of $119.09 from 2020-12-09

1 week (2021-01-07) 3.56%
1 month (2020-12-17) -1.07%
3 months (2020-10-15) -3.56%
6 months (2020-07-15) 14.59%
1 year (2020-01-15) 37.09%
2 years (2019-01-15) 3.51%
3 years (2018-01-13) N/A
5 years (2016-01-15) 52,501.59%

Madrigal Pharmaceuticals financials

Gross profit TTM USD$0
Return on assets TTM -27.81%
Return on equity TTM -46.81%
Profit margin 0%
Book value $18.731
Market capitalisation USD$1.8 billion

TTM: trailing 12 months

Shorting Madrigal Pharmaceuticals shares

There are currently 2.4 million Madrigal Pharmaceuticals shares held short by investors – that's known as Madrigal Pharmaceuticals's "short interest". This figure is 4.5% down from 2.5 million last month.

There are a few different ways that this level of interest in shorting Madrigal Pharmaceuticals shares can be evaluated.

Madrigal Pharmaceuticals's "short interest ratio" (SIR)

Madrigal Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Madrigal Pharmaceuticals shares currently shorted divided by the average quantity of Madrigal Pharmaceuticals shares traded daily (recently around 120606.97201018). Madrigal Pharmaceuticals's SIR currently stands at 19.65. In other words for every 100,000 Madrigal Pharmaceuticals shares traded daily on the market, roughly 19650 shares are currently held short.

However Madrigal Pharmaceuticals's short interest can also be evaluated against the total number of Madrigal Pharmaceuticals shares, or, against the total number of tradable Madrigal Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Madrigal Pharmaceuticals's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Madrigal Pharmaceuticals shares in existence, roughly 150 shares are currently held short) or 0.2987% of the tradable shares (for every 100,000 tradable Madrigal Pharmaceuticals shares, roughly 299 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Madrigal Pharmaceuticals.

Find out more about how you can short Madrigal Pharmaceuticals stock.

Madrigal Pharmaceuticals share dividends

We're not expecting Madrigal Pharmaceuticals to pay a dividend over the next 12 months.

Have Madrigal Pharmaceuticals's shares ever split?

Madrigal Pharmaceuticals's shares were split on a 1:35 basis on 25 July 2016. So if you had owned 35 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Madrigal Pharmaceuticals shares – just the quantity. However, indirectly, the new 3400% higher share price could have impacted the market appetite for Madrigal Pharmaceuticals shares which in turn could have impacted Madrigal Pharmaceuticals's share price.

Madrigal Pharmaceuticals share price volatility

Over the last 12 months, Madrigal Pharmaceuticals's shares have ranged in value from as little as $56.82 up to $136.81. A popular way to gauge a stock's volatility is its "beta".

MDGL.US volatility(beta: 1.47)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Madrigal Pharmaceuticals's is 1.469. This would suggest that Madrigal Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Madrigal Pharmaceuticals overview

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials for the treatment of NASH and hyperlipidemia. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site